Vigil Neuroscience, Inc.

As of June 9, 2025, the trend has shifted to bullish, supported by positive daily moving averages and a bullish weekly MACD, although caution is warranted due to a bearish weekly RSI.

Vigil Neuroscience, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $22 million and a market cap of $368.12 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -133.18%.

As of Jun 18, Vigil Neuroscience, Inc. has a market capitalization of 368.12 million and reported net sales of 0.00 million with a net profit of -86.73 million over the last four quarters. Shareholder's funds were 71.64 million, and total assets amounted to 117.69 million as of Dec 24.